NCT03172910: A trial that was reported late by Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
This trial has reported, although it was 962 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03172910 |
|---|---|
| Title | Phase 2 Placebo-Controlled, Single-Site, Single-Blind Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | May 8, 2017 |
| Completion date | Nov. 12, 2019 |
| Required reporting date | Nov. 12, 2022, midnight |
| Actual reporting date | July 1, 2025 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 962 |